文献速递肝胆胰外科围术期管理与 ERAS

围术期多重耐药菌损害胰腺手术临床结局:抗菌预防的漏靶

Perioperative multidrug-resistant bacteria impair clinical outcome after pancreatic surgery: Missed targets of antibiotic prophylaxis.
PubMed 文献 · Surgery · 2025-10-07

该回顾性单中心队列纳入2018年1月至2022年12月接受择期胰腺手术且有完整术前筛查拭子的212例患者,其中44例(20.75%)围术期多重耐药菌阳性。多重耐药菌阳性患者术后胰腺瘘(B/C级)、胰腺切除术后出血和再手术率均显著升高(均P<.0001),胰腺瘘进展为出血和再手术的比例也显著更高(37.84% vs 3.92%;P<.0001)。

要点

  • 围术期多重耐药菌阳性与胰腺术后瘘、出血和再手术率显著升高相关。
  • 多重耐药菌阳性患者胰腺瘘进展为出血和再手术的比例为37.84% vs 3.92%。
  • 常见围术期抗菌药物对多重耐药菌的耐药率较高,需考虑术前去定植和广谱预防。

核心结论

  • 术前和术后多重耐药菌定植均对胰腺手术后结局产生不良影响。
  • 胰腺瘘是多重耐药菌阳性患者发生严重并发症的关键原因。

研究设计与样本

  • 回顾性单中心队列研究,纳入2018年1月至2022年12月接受择期胰腺手术且有完整术前筛查拭子的212例患者。

主要发现

  • 212例中168例(79.25%)为多重耐药菌阴性,44例(20.75%)围术期多重耐药菌阳性,其中19例术前检出、25例术后检出。
  • 多重耐药菌阳性患者术后胰腺瘘(B/C级)、胰腺切除术后出血和再手术率均显著高于阴性患者(均P<.0001)。
  • 多重耐药菌阳性患者主要并发症率、重症监护时间和住院时间均增加(均P<.0001)。
  • 多重耐药菌阳性患者胰腺瘘进展为出血和再手术的比例为37.84% vs 3.92%(P<.0001)。
  • 亚组分析显示术前和术后检出多重耐药菌的患者术后结局无差异。

关键数值与推荐

  • 常见围术期抗菌药物(包括甲硝唑/第二代头孢菌素或哌拉西林/他唑巴坦)对多重耐药菌的固有或获得性耐药率较高。

临床怎么用

  • 对高风险胰腺手术患者应考虑术前去定植、广谱围术期抗菌药物预防和术后继续抗菌药物治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant bacteria represent major concerns in perioperative medicine. The extent to which preoperative colonization and postoperative detection of multidrug-resistant bacteria affect outcome in pancreatic surgery is largely unknown. Microbiome analyses provide insights into appropriate perioperative antibiotic prophylaxis. METHODS: This was a retrospective, single-center cohort study of patients who underwent elective pancreatic surgery between January 2018 and December 2022 with a complete set of preoperative screening swabs. RESULTS: Of 212 patients, n = 168 (79.25%) were classified as multidrug-resistant negative, whereas 44 (20.75%) were tested multidrug-resistant positive perioperatively. Among these, 19 had preoperative detection of multidrug-resistant bacteria and 25 had postoperative detection of multidrug-resistant bacteria. No differences in baseline characteristics were observed. Inflammatory parameters, including blood leukocytes and C-reactive protein, were elevated perioperatively in patients who were multidrug-resistant positive. Postoperative outcomes were significantly impaired in patients who were multidrug-resistant positive compared with those who were multidrug-resistant negative, including greater rates of pancreatic fistula (grade B/C), postpancreatectomy hemorrhage, and reoperation (all P < .0001). Major complication rates, length of intensive care, and in-hospital stay were increased (all P < .0001). Progression of pancreatic fistula to hemorrhage and reoperation was particularly high in patients who were multidrug-resistant positive (37.84% vs 3.92%; P < .0001). Subgroup analyses revealed no differences in postoperative outcomes between patients who were preoperatively tested multidrug-resistant positive and those who were postoperatively tested multidrug-resistant positive. High intrinsic or acquired bacterial resistance rates were observed against commonly used perioperative antibiotics in pancreatic surgery, including metronidazole/second-generation cephalosporins or piperacillin/tazobactam. CONCLUSION: Both preoperative and postoperative colonization with multidrug-resistant bacteria have deleterious effects on postoperative outcomes. Pancreatic fistula is a crucial cause for severe morbidity in patients who are multidrug-resistant positive. Preoperative decolonization, broad-spectrum perioperative antibiotic prophylaxis, and continued postoperative antibiotics should be considered for high-risk pancreatic surgery patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Noll J, Roosen H, Fritzenwanker M, et al. Perioperative multidrug-resistant bacteria impair clinical outcome after pancreatic surgery: Missed targets of antibiotic prophylaxis. Surgery. 2025. PMID: 41061330. doi:10.1016/j.surg.2025.109717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。